Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in two upcoming investor conferences. The first is the 22nd Annual Needham Virtual Healthcare Conference, where a fireside chat is scheduled for April 18, 2023, at 8:45 a.m. EDT, with one-on-one meetings throughout the conference from April 17-20, 2023. The second event is the H.C. Wainwright BioConnect Investor Conference in New York City, featuring a fireside chat on May 2, 2023, at 2:30 p.m. EDT. Investors can access live webcasts and archived recordings of these chats via the company’s website for 90 days post-event. Phathom focuses on novel treatments for gastrointestinal diseases, with exclusive rights to vonoprazan, a potassium-competitive acid blocker.

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:

• 22nd Annual Needham Virtual Healthcare Conference, including a scheduled fireside chat on Tuesday, April 18, 2023 at 8:45 a.m. EDT. Management will also participate in one-on-one meetings throughout the conference, which runs from April 17-20, 2023.
  
  
• H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City. Management will participate in a fireside chat on Tuesday, May 2, 2023 at 2:30 p.m. EDT and one-on-one meetings throughout the day.
  

To access the live webcast and archived recordings of the fireside chats, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following each event.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2023 Phathom Pharmaceuticals. All rights reserved.

FAQ

What investor conferences will Phathom Pharmaceuticals participate in April 2023?

Phathom Pharmaceuticals will participate in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023, with a fireside chat on April 18, 2023.

When is Phathom's fireside chat at the H.C. Wainwright BioConnect Investor Conference?

Phathom's fireside chat at the H.C. Wainwright BioConnect Investor Conference is scheduled for May 2, 2023, at 2:30 p.m. EDT.

How can I access the Phathom Pharmaceuticals investor conference webcasts?

Investors can access the live webcasts and archived recordings of Phathom's fireside chats via the company's website for 90 days after each event.

What is the main focus of Phathom Pharmaceuticals?

Phathom Pharmaceuticals specializes in developing and commercializing novel treatments for gastrointestinal diseases.

What product rights does Phathom Pharmaceuticals hold?

Phathom holds exclusive rights in the U.S., Europe, and Canada for vonoprazan, a first-in-class potassium-competitive acid blocker.